Fill and half-stopper insertion

Ambient · pre-freeze

The liquid drug product formulation is filled into the lyo vial under aseptic conditions - typically on an aseptic filling line equipped with a stopper insertion station. The two-leg lyo stopper is placed into each vial in the half-inserted position (also called the "I-position" in some lyophilizer specifications): the stopper legs are inside the vial neck but the stopper head sits above the neck opening, leaving a defined vapour channel between the legs and the neck inner wall. The filled, half-stoppered vials are loaded onto the lyophilizer shelf in trays.

Product frozen to −40°C to −50°C

−40°C to −50°C

The lyophilizer shelf temperature is reduced to freeze the liquid product - typically to −40°C to −50°C, held for a defined soak time to ensure the entire fill volume is solidly frozen. The vial glass must withstand this rapid temperature decrease without thermal shock cracking. The half-inserted stopper remains in position, and the frozen product is a solid block (the pre-lyophilized matrix). The ice crystal structure formed during freezing determines the pore structure of the final dried cake, making freeze rate control a critical formulation development parameter.

Sublimation under vacuum

−20°C to +25°C shelf · <200 mTorr

The chamber is evacuated to below the triple point of water (typically 100–200 mTorr), and the shelf temperature is raised. Under these conditions, frozen water sublimes directly from solid ice to vapour - bypassing the liquid phase - and the vapour escapes from the vial through the vapour channel between the half-inserted lyo stopper legs and the neck inner wall. The dried cake forms progressively as the ice front recedes. This stage typically takes the longest time in the lyo cycle and is critically dependent on the vial's vapour conductance (the rate at which vapour can escape through the half-open stopper channel).

Shelf closes stoppers under vacuum

+20°C to +60°C shelf · stopper closed

Secondary drying removes bound (non-frozen) water from the dried cake at higher shelf temperatures. At the end of the secondary drying phase, the lyophilizer shelf descends and applies a controlled downward force to all vials simultaneously - mechanically pushing the two-leg stopper from the half-inserted position to the fully seated position, sealing all vials hermetically under vacuum (or under an inert gas atmosphere if the product is oxygen-sensitive). The sealed vials are then transferred to the capping station where the 20mm aluminium flip off cap is crimped over the stoppered neck to lock the stopper in position permanently.

Monoclonal antibodies, recombinant proteins, fusion proteins, and antibody-drug conjugates are frequently lyophilized because their physical and chemical stability in liquid form is insufficient for commercial shelf-life targets. The liquid formulation is too prone to aggregation, deamidation, oxidation, or hydrolysis to store as a liquid at room temperature for 18–24 months. Lyophilization removes the water that drives these degradation pathways - the dried protein cake, stored under vacuum or inert gas in the sealed lyo vial, achieves the 24–36 month shelf life required for commercial product distribution.

 Monoclonal antibodies and biosimilar mAbs

Bispecific antibodies and antibody-drug conjugates

Recombinant growth factors and cytokines

Lyophilized enzyme replacement therapies

Many beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) and antifungal agents degrade rapidly in aqueous solution - their shelf life as a liquid injectable at room temperature would be insufficient for commercial distribution. Lyophilization of the active pharmaceutical ingredient (with appropriate excipients) produces a stable powder cake that is reconstituted with Water for Injection immediately before intravenous or intramuscular administration. The reconstituted solution is used within hours - the lyophilized form provides years of shelf life under appropriate storage conditions.

Beta-lactam antibiotics (cephalosporins, carbapenems)

Amphotericin B and antifungal agents

Vancomycin and glycopeptide antibiotics

Aztreonam and monobactam antibiotics

Live-attenuated and subunit vaccines are frequently lyophilized to achieve thermostable formulations suitable for cold-chain distribution and long-term storage. Lyophilized peptide injectables - where the peptide is unstable in aqueous solution or must be stored without a preservative - are also produced in lyo vials, reconstituted immediately before injection. Diagnostic reagents, reference standards, and assay calibrators requiring precise concentration and long shelf life are similarly lyophilized in vials for stability.

Live-attenuated and subunit vaccines

Peptide injectables - aqueous-unstable formulations

Diagnostic assay calibrators and reference standards

Research lyophilization - custom formulations